In the recipient operation, evisceration of the liver, stomach, pancreaticoduodenal complex, spleen, small intestine, and portion of the large intestine was performed with preservation of the vena cava with ''piggyback'' implantation of the graft. The descending and sigmoid colon were preserved in all of the recipients. The arterial inflow for the graft was established through a common patch of aorta
Objective: To evaluate the clinical outcomes of multivisceral transplantation (MVT) in the setting of diffuse thrombosis of the portomesenteric venous system. Background: Liver transplantation (LT) in the face of cirrhosis and diffuse portomesenteric thrombosis (PMT) is controversial and contraindicated in many transplant centers. LT using alternative techniques such as portocaval hemitransposition fails to eliminate complications of portal hypertension. MVT replaces the liver and the thrombosed portomesenteric system. Methods: A database of intestinal transplant patients was maintained with prospective analysis of outcomes. The diagnosis of diffuse PMT was established with dual-phase abdominal computed tomography or magnetic resonance imaging with venous reconstruction. Results: Twenty-five patients with grade IV PMT received 25 MVT. Eleven patients underwent simultaneous cadaveric kidney transplantation. Biopsyproven acute cellular rejection was noted in 5 recipients, which was treated successfully. With a median follow-up of 2.8 years, patient and graft survival were 80%, 72%, and 72% at 1, 3, and 5 years, respectively. To date, all survivors have good graft function without any signs of residual/recurrent features of portal hypertension. Conclusions: MVT can be considered as an option for the treatment of patients with diffuse PMT. MVT is the only procedure that completely reverses portal hypertension and addresses the primary disease while achieving superior survival results in comparison to the alternative options. Liver transplantation (LT) in patients with portal vein thrombosis is now routinely performed in most cases of noncomplex portal vein thrombosis; however, in patients with diffuse portomesenteric thrombosis (PMT), it is technically challenging and associated with inferior posttransplant survival when compared to patients with a patent portal vein. [1] [2] [3] Many liver transplant centers consider diffuse PMT a contraindication for LT. Portal vein thrombosis can be divided into 4 stages according to the extent of the disease (Table 1) . 1 Stages I and II can be removed with eversion thromboendovenectomy combined with proximal dissection of the portal vein to reestablish the blood flow to the transplanted liver. 4 In these circumstances, surgical techniques utilizing the systemic venous circulation such as cavoportal hemitransposition, renoportal anastomosis, and arterialization of the portal vein have been attempted to establish venous flow to the recipient portal vein. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Even though venous flow can be reestablished to the transplanted liver using systemic drainage, from a physiologic perspective, these approaches do not decompress the recipient's underlying portal hypertension, leaving the patient with unmanaged esophageal varices, splenomegaly, and ascites. In addition, due to increased pressure in the inferior vena cava many patients develop renal failure during the postoperative period. 17 The alternative approach described here would be to completely replace the recipient's portomesenteric venous system by performing a multivisceral transplant (MVT). [18] [19] [20] MVT is the only surgical option that has the potential to completely reverse all of the patient's baseline disease, including manifestations of cirrhosis and portal hypertension. At our center, the use of MVT has become the option of choice for the management of potential liver transplant recipients with diffuse PMT, when all attempts to perform LT with mesenteric drainage fail. This report represents the first series of patients in which long-term outcomes are presented. [19] [20] [21] Our experience includes 25 patients in which an MVT including liver, pancreaticoduodenal complex, stomach, and small intestine with or without a kidney, was performed in the presence of diffuse thrombosis of the portomesenteric system ( Fig. 1 ).
MATERIALS AND METHODS
A retrospective analysis of all MVT recipients with the primary diagnosis of PMT from July 2004 to July 2009 was performed with data obtained from the intestinal transplant database maintained at our center (IRB No. 0611-75). The diagnosis of diffuse thrombosis of the portomesenteric system was confirmed in all recipients during the pretransplant evaluation either by computed tomographic imaging of the abdomen with venous phase or magnetic resonance imaging with venous reconstruction. The multivisceral graft was procured using standard techniques described elsewhere. 22 Patients, in whom LT alone was possible either with eversion thromboendovenectomy or with portomesenteric vein grafts, were analyzed separately. LT was always attempted in all recipients. The presence of abdominal comorbidities was not by itself a reason to perform MVT.
Donor selection was determined by the recipient size, peritoneal space, and medical history of the donor. Donor cytomegalovirus (CMV) status, hypernatremia, downtime, and requirement of pressors on its own did not preclude use of the grafts. Median donor age for adult recipients was 21 (9-49) years and 5.8 (3.7-7.9) years for the pediatric recipients. containing the donor celiac trunk and the superior mesenteric artery (Fig. 2) .
This was reconstructed on the backbench to create a single conduit using either the donor supraceliac aorta or the donor common iliac artery bifurcation. The conduit was then anastomosed to the infrarenal aorta of the recipient. The venous outflow was established through the anastomosis of the suprahepatic vena cava of the donor into a common cuff created of the 3 hepatic veins of the recipient. Gastrointestinal continuity was reestablished by anastomosing the donor stomach to the recipient esophagus or stomach. Nissen fundoplication and pyloroplasty were routinely performed. Distal intestinal continuity was reestablished by performing an ileocolic anastomosis with a terminal ileostomy for endoscopic monitoring of the graft. In patients who required a simultaneous renal transplant, the kidney was routinely placed on a pulsatile perfusion pump. Originally, the renal transplant was performed immediately after the multivisceral implantation but, more recently, we have delayed the transplant for 24 to 48 hours when the recipients are typically more hemodinamically stable.
Induction immunosuppression included rabbit antithymocyte globulin (5 doses of 2 mg/kg for adults and 4 doses of 2 mg/kg for pediatric recipients), rituximab (150 mg/m 2 BSA), and solumedrol bolus with taper. The first dose of thymoglobulin was typically given intraoperatively after reperfusion of the graft. Maintenance immunosuppression consisted of tacrolimus and prednisone. Enteral tacrolimus was started immediately after transplantation; intravenous tacrolimus was used when adequate levels were not achieved with enteral therapy by the end of the first week posttransplant. Target tacrolimus levels between 8 and 12 ng/dL were maintained for the first 3 months and then decreased to 5 to 8 ng/dL. Broad-spectrum antibiotics (vancomycin, piperacillin-tazobactam or meropenem, fluconazole) and antiviral agents (intravenous gancyclovir and cytogam) were continued for 7 postoperative days. All patients received daily aspirin, and additional anticoagulation was only used in patients with a primary hypercoagulable defect. Patients received daily trimethoprim/sulfamethoxazole for 24 months after transplant for pneumocystis jiroveci pneumonia prophylaxis. Endoscopic surveillance for rejection was performed by serial magnification endoscopy through the ileostomy according to our protocol ( Table 2) .
The ileostomy was routinely taken down 3 to 6 months postoperatively, after which colonoscopy was required for future surveillance. Ileoscopy or colonoscopy outside the surveillance protocol was performed for increased stool output to rule out acute rejection or viral diseases.
RESULTS

Selection of Surgical Procedure
Over a 5-year period, 31 patients with PMT were evaluated for MVT at our center. Fifteen (48%) patients were referred from another liver transplant center where they were deemed unsuitable for LT due to extensive PMT. All cases were reviewed and approved by our multidisciplinary transplant committee before inclusion in the transplant list. Abdominal computed tomography/magnetic resonance imaging were also reviewed in conjunction with an experienced radiologist to confirm the diagnosis of extensive PMT. Seventeen patients (55%) had additional abdominal comorbidities (patients marked by " ‡" in Table 3 ).
In the operating room, all efforts were made to reestablish venous flow to the portal vein using the mesenteric venous system to perform an isolated LT. In 6 of 31 (19%), patients LT only was possible. In 3 of 6 patients, optimal portal flow was established by proximal dissection of the portomesenteric bifurcation with extensive thromboendovenectomy, and in the other 3 patients, alternative venous flow via construction of a jump graft from distal superior or inferior mesenteric vein was possible ( Table 3 ). These 6 patients were excluded from detailed analysis presented in this study. In these patients, the pancreas was separated from the liver and intestine in the back table and used as an isolated graft in another recipient.
Recipient Characteristics
Recipient demographics are described in Table 4 . All but 2 recipients were adults (median age 53 [2.5-67]). Median waiting time on the transplant list was 26 (3-167) days. Four recipients (13%) had previously undergone 5 liver transplants and developed diffuse PMT. Nine (29%) recipients underwent a simultaneous renal transplant for pretransplantation renal insufficiency. Four (13%) patients had acute PMT with irreversible liver failure. Two patients did not have endstage liver disease (marked by ‡ in Table 3 ). Twenty-three patients received ABO identical grafts and 2 received compatible ABO grafts. Median Model for End-Stage Liver Disease (MELD) score was 22 
Operative Details
Median cold ischemia time was 8 (5-13) hours, and warm ischemia time was 22 (18-28) minutes. Median operative time was 10 (7-16) hours. Median blood transfusion requirement was 29 units. Intraoperative coagulopathy was managed with elective packing of the abdominal cavity and planned reexploration in 5 patients.
Posttransplant Outcomes
There were no operative deaths and of 25 patients 1 (4%) died within 30 days of transplantation. Median length of stay in intensive care unit was 7 days and in hospital was 40 days. Five patients died within the first year posttransplant (80% one-year survival). None of the deaths were attributed to either cellular or vascular rejection.
None of the patients developed chronic rejection. All patients were discharged without the need for parenteral nutrition. The causes of death are listed in Table 5 .
The actuarial patient survival was 80% at 1 year, and 72% at 3 and 5 years with a median follow-up of 2.78 (1.2-6.2) years ( Fig. 3) .
Recipients without simultaneous renal transplant (16; 64%) had relatively better outcomes (88% at 1, and 80% at 3 and 5 years) when compared with those requiring simultaneous renal transplants; however, this was not statistically significant (log rank; P = 0.08). Six (24%) recipients developed viral infections (4 CMV, 2 Epstein Barr Virus). Cutaneous graft versus host disease (GVHD) was found in 3 patients. Five (20%) patients experienced acute cellular rejection (2 mild, 1 moderate, and 3 severe). Antibody mediated rejection was not diagnosed in any of the patients. Readmission rates in the first year after transplant ranged from 0 to 9 (median 3). All survivors are taking an oral diet without the need for enteral or parenteral supplementation.
Surgical Complications
Surgical complications were encountered in 14 patients. Eight (57%) patients required reexplorations for various reasons (excluding planned take backs for renal transplant (n = 5). Three patients developed wound dehiscence. Two patients required reexploration for hemorrhage. One patient was reexplored for small bowel obstruction and gastrointestinal anastomotic leak was found in 2 ( Table 6 ). Residual or recurrent features of portal hypertension (gastroesophageal varices and/or ascites) were not observed in any of the patients. all patients. The average weighted hospital reimbursement for the study cohort was $686,000.
DISCUSSION
It is estimated that 2% to 26% of patients with otherwise compensated cirrhosis are found to have portal vein thrombosis during the evaluation for LT. 1 In patients with complex portal vein thrombosis, LT remains challenging, with relatively worse outcomes. 23 The overall patient survival in our study (80% and 72% at 1 and 3 years) is numerically higher than that reported in the largest experience of cavoportal hemitransposition (n = 23) (60% and 48% at 1 and 3 years, respectively). 10 Although such comparisons are not valid, a controlled study comparing the 2 procedures is unlikely to occur. Undoubtedly, LT is possible in select cases of extensive portal vein thrombosis with intraoperative eversion thromboendovenectomy or with the use of a venous jump graft to the distal mesenteric veins; as reported in 6 patients in this study. We believe that having a multivisceral graft available in the operating room played an important role in management of these patients as it allowed more aggressive dissection of the mesenteric system. These patients had 1-year survival of 83% and overall survival of 67% at a median follow-up of 2.8 (1.7-4.7) years. Patients with stage I/II portal vein thrombosis routinely receive LT at our center and were not included in this study. LT with portomesenteric inflow was attempted in all patients in this study, which required aggressive dissection of the portomesenteric venous system. In some cases, particularly in the patients with previous surgical comorbidities and severe adhesions, dissection of the portomesenteric venous system had to be aborted due to excessive bleeding, or inability to find a patent branch of the mesenteric venous circulation, which prompted MVT (Fig. 4) .
In the remaining cases, MVT was performed after having exhausted the options of eversion thromboendovenectomy or a venous bypass graft from the mesenteric venous system. The use of systemic venous circulation (eg, cavoportal hemitransposition) was not considered for 2 main reasons: (i) its inability to completely decompress the portal venous system and (ii) its association with complications that result from increased systemic venous pressure (renal failure, ascites, and leg edema). As reported in the Miami series, 30.4% (7/23) patients experienced gastrointestinal bleeding and ascites was noted in almost all patients after cavoportal hemitransposition. 10 Adding splenectomy and gastric devascularization to LT is another possible surgical option in this setting; however, the benefit of this procedure is temporary. 24 In patients with a patent splenorenal shunt, decompression of the gastrosplenic venous system can be achieved with a renoportal anastomosis. 25, 26 The anastomosis of the portal vein to the renal vein without a patent splenorenal shunt may not decompress the native portal system although this may have some advantage over a cavoportal hemitransposition by not interrupting the caval flow and preventing deleterious effects to the right kidney. The possible "siphon effect'' caused by cavoportal or renoportal reconstruction has not been demonstrated in the literature. Without decompression of the portomesenteric venous system, LT in the setting of PMT converts a cirrhotic patient with portal hypertension in to a noncirrhotic patient with portal hypertension. The experience with MVT in the setting of diffuse PMT is limited, [19] [20] [21] 27 which makes it difficult to compare the outcomes after MVT to that after other surgical option. Intestinal transplantation/MVT has experienced tremendous progress in the last decade. 28 Several factors including improvements in the surgical technique, use of induction immunosuppression, and better understanding of the immunological processes may be responsible for the improved outcomes. An improvement in long-term outcomes after MVT has also been seen at our center. 29 Some of the cases reported in this study were performed in the beginning of our program and therefore are a part of our learning curve. However, in a Cox regression analysis, transplant year did not have any significant impact on the survival outcomes.
Of 9 patients who received simultaneous MVT and kidney transplants, 5 are alive. The overall mortality was higher in these patients than in those receiving MVT only, but this difference was not statistically significant. This might reflect the sample size, however, as the published literature shows significantly higher posttransplant mortality in patients requiring dialysis before LT and therefore it might be reasonable to conclude that this would be the case for MVT recipients with prior renal insufficiency. In our opinion, this should remain a primary concern during patient selection and evaluation. 30, 31 Delayed graft function was noticed in the first 4 patients who received the kidney transplant at the end of MVT. We believed this was due to the relative hemodynamic instability and frequent requirement for inotropes in the early postoperative course. To prevent this, we have changed our approach, and the renal grafts are now placed on a pulsatile perfusion machine for 24 to 48 hours until the recipients are hemodinamically stable and better prepared to receive the renal graft. In the 16 patients who received MVT only, patient and graft survival was higher at 1 and 3 years (88% and 80%, respectively).
The survival in this group compares better with the Miami cavoportal cases because none of the patients in their series had a combined liver/kidney transplant. We believe that the outcomes after MVT are encouraging considering the morbidity and surgical complexity of this patient population. In addition to the anatomic complexities, some of the patients in our series were physiologically challenged. Their MELD/PELD scores perhaps underscored the magnitude of their disease. Four patients with acute PMT presented with multiple organ dysfunction at the time of transplant. These patients underwent massive resection of gangrenous small bowel in the setting of acute liver failure due to extensive thrombosis without recovery of the liver function. In these patients, MVT was considered as the best option as an isolated LT was not possible.
MVT in the setting of diffuse PMT can be challenging due to the presence of collateral veins, and significant blood loss can occur at the time of resection of native organs. The intestinal component of the MVT does bring additional risks such as rejection, dehydration associated with high output from the intestinal graft, and GVHD. MVT has a higher cost and higher admission rates than LT in the absence of complex portal vein thrombosis. However, patients undergoing LT with systemic drainage have longer periods of hospital admission, requiring dialysis and reoperations, which makes it very difficult to compare the groups. The rate of acute cellular rejection in this study was 24%; however, only 3 patients experienced severe acute cellular rejection. The inclusion of the liver allograft offers immunological privilege to the MVT graft, and the overall rate of rejection is lower in MVT when compared to that with isolated intestinal transplants. 21, 27 Chronic rejection of the intestinal graft is a particular problem in liver-free intestinal grafts, 21 as acute rejection usually sets the stage for graft loss to chronic rejection. We anticipate that chronic rejection may not be a major problem in the study population due to inclusion of the liver graft, as found in another report with larger number of patients and longer follow-up. 21 None of our patients has progressed to chronic rejection to date.
Portomesenteric thrombosis is the most common cause of portal hypertension in noncirrhotic patients. Patients with extrahepatic portal hypertension tolerate individual episodes of variceal bleeding quite well. However, a few patients can experience life-threatening episodes of gastrointestinal bleeding after exhausting all medical and surgical options. MVT can be considered in this setting. In our series, 2 patients with extrahepatic portal hypertension due to PMT underwent MVT. Readmission rates during the first year after transplant ranged from 0 to 9 admissions (median 3). As expected, most readmissions occurred during the first 90 days after transplant (80%) with dehydration due to high ostomy output being the most common diagnosis. Average hospital reimbursement for MVT in these series was $686,000. Even though reimbursements are higher compared with isolated liver transplant, it is difficult to compare these groups because LT in the setting of diffuse mesenteric thrombosis where alternative vascular approaches are used have significantly longer postoperative stays with multiple complications including ascites, edema, and renal failure requiring posttransplant dialysis. 17
CONCLUSIONS
Survival for patients receiving intestinal transplantation and MVT has improved tremendously in the last decade. MVT can be considered as an option for the treatment of patients with diffuse PMT. MVT is the only procedure that completely reverses portal hypertension and addresses the primary disease while achieving superior survival results in comparison with the alternative options.
